Adalimumab/certolizumab pegol/infliximabPsoriasis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2016年 / 1586卷 / 1期

关键词：

D O I：

10.1007/s40278-016-14049-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：23 / 23

相关论文

共 50 条

[1] Adalimumab/certolizumab-pegol/infliximabPsoriasis : case report
Reactions Weekly, 2016, 1595 (1) : 15 - 15
[2] Adalimumab/certolizumab pegol/infliximabPsoriasis and psoriasiform eruptions: 14 case reports
Reactions Weekly, 2017, 1660 (1) : 16 - 16
[3] Adalimumab/certolizumab pegol/infliximabDisseminated tuberculosis: case report
Reactions Weekly, 2017, 1682 (1) : 20 - 20
[4] Adalimumab/Certolizumab-pegol/MethotrexateMiliary histoplasmosis: case report
Reactions Weekly, 2024, 2028 (1) : 23 - 23
[5] Adalimumab/certolizumab pegol/ciclosporin/infliximabMycobacterium marinum: case report
Reactions Weekly, 2016, 1631 (1) : 17 - 17
[6] Adalimumab/infliximabPsoriasis: case report
Reactions Weekly, 2011, 1350 (1) : 8 - 8
[7] Adalimumab/certolizumab-pegol/sulfasalazineRenal sarcoidosis and lack of efficacy: case report
Reactions Weekly, 2021, 1885 (1) : 25 - 25
[8] Adalimumab/certolizumab pegol/infliximabAnti-TNF induced lupus: case report
Reactions Weekly, 2017, 1645 (1) : 20 - 20
[9] Certolizumab pegol/methotrexatePancytopenia: case report
Reactions Weekly, 2014, 1492 (1) : 16 - 16
[10] Certolizumab pegol/leflunomidePyomyositis: case report
Reactions Weekly, 2018, 1720 (1) : 73 - 73

← 1 2 3 4 5 →